BRPI0617693A2 - azitromicina para o tratamento de rosácea granulomatosa - Google Patents
azitromicina para o tratamento de rosácea granulomatosa Download PDFInfo
- Publication number
- BRPI0617693A2 BRPI0617693A2 BRPI0617693-3A BRPI0617693A BRPI0617693A2 BR PI0617693 A2 BRPI0617693 A2 BR PI0617693A2 BR PI0617693 A BRPI0617693 A BR PI0617693A BR PI0617693 A2 BRPI0617693 A2 BR PI0617693A2
- Authority
- BR
- Brazil
- Prior art keywords
- rosacea
- azithromycin
- treatment
- granulomatous
- therapy
- Prior art date
Links
- 201000004700 rosacea Diseases 0.000 title claims abstract description 43
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 33
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 3
- 230000009897 systematic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241001303601 Rosacea Species 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 9
- 206010018691 Granuloma Diseases 0.000 abstract description 4
- 238000007910 systemic administration Methods 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 230000003442 weekly effect Effects 0.000 description 7
- 206010033733 Papule Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002483 medication Methods 0.000 description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 5
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 229960005280 isotretinoin Drugs 0.000 description 4
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 3
- 229940126702 topical medication Drugs 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940063189 metrogel Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- -1 tacrolimus Chemical compound 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OLUNPKFOFGZHRT-YGCVIUNWSA-N Naftifine hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OLUNPKFOFGZHRT-YGCVIUNWSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229940053636 finacea Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940089350 klaron Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 229940100527 naftin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73484305P | 2005-11-09 | 2005-11-09 | |
| US60/734.843 | 2005-11-09 | ||
| PCT/US2006/043339 WO2007086978A2 (en) | 2005-11-09 | 2006-11-08 | Azithromycin for treatment of granulomatous rosacea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0617693A2 true BRPI0617693A2 (pt) | 2011-08-02 |
Family
ID=38309684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0617693-3A BRPI0617693A2 (pt) | 2005-11-09 | 2006-11-08 | azitromicina para o tratamento de rosácea granulomatosa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070105788A1 (https=) |
| EP (1) | EP1945227A4 (https=) |
| JP (1) | JP2009514963A (https=) |
| CN (1) | CN101304750A (https=) |
| AU (1) | AU2006336612A1 (https=) |
| BR (1) | BRPI0617693A2 (https=) |
| CA (1) | CA2626551A1 (https=) |
| RU (1) | RU2008122964A (https=) |
| WO (1) | WO2007086978A2 (https=) |
| ZA (1) | ZA200804896B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124123B2 (en) * | 2007-09-05 | 2012-02-28 | Dow Pharmaceutical Sciences, Inc. | Controlled release azithromycin solid dosages forms |
| US8143227B2 (en) * | 2007-09-05 | 2012-03-27 | Dow Pharmaceutical Sciences, Inc. | Azithromycin for treatment of skin disorders |
| MX2010009493A (es) * | 2008-02-28 | 2010-12-20 | Rp Scherer Technologies Llc | Proceso para minimizar el polimorfismo. |
| WO2010006306A1 (en) * | 2008-07-10 | 2010-01-14 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
| WO2010085572A1 (en) * | 2009-01-23 | 2010-07-29 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with azithromycin |
| RU2425682C1 (ru) * | 2010-04-28 | 2011-08-10 | Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") | Способ лечения акне средней степени тяжести |
| US20130274214A1 (en) * | 2010-12-29 | 2013-10-17 | Inspire Pharmaceuticals, Inc. | Method for treating blepharitis |
| JP5986632B2 (ja) | 2011-06-28 | 2016-09-06 | メディシス ファーマシューティカル コーポレイション | 高用量粘膜接着性メトロニダゾール水系ゲル製剤および細菌性膣炎を治療するためのそれらの使用 |
| WO2014100569A1 (en) * | 2012-12-20 | 2014-06-26 | Medicis Pharmaceutical Corporation | High dosage topical metronidazole gel formulations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2446356C (en) * | 2001-05-09 | 2012-07-10 | The Regents Of The University Of Michigan | Use of compositions for treating rosacea |
-
2006
- 2006-11-08 BR BRPI0617693-3A patent/BRPI0617693A2/pt not_active IP Right Cessation
- 2006-11-08 RU RU2008122964/14A patent/RU2008122964A/ru not_active Application Discontinuation
- 2006-11-08 WO PCT/US2006/043339 patent/WO2007086978A2/en not_active Ceased
- 2006-11-08 CA CA002626551A patent/CA2626551A1/en not_active Abandoned
- 2006-11-08 JP JP2008540128A patent/JP2009514963A/ja active Pending
- 2006-11-08 US US11/594,451 patent/US20070105788A1/en not_active Abandoned
- 2006-11-08 CN CNA2006800418105A patent/CN101304750A/zh active Pending
- 2006-11-08 EP EP06849873A patent/EP1945227A4/en not_active Withdrawn
- 2006-11-08 AU AU2006336612A patent/AU2006336612A1/en not_active Abandoned
-
2008
- 2008-06-05 ZA ZA200804896A patent/ZA200804896B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009514963A (ja) | 2009-04-09 |
| EP1945227A2 (en) | 2008-07-23 |
| WO2007086978A2 (en) | 2007-08-02 |
| CN101304750A (zh) | 2008-11-12 |
| EP1945227A4 (en) | 2009-09-30 |
| WO2007086978A3 (en) | 2007-11-22 |
| AU2006336612A1 (en) | 2007-08-02 |
| CA2626551A1 (en) | 2007-08-02 |
| US20070105788A1 (en) | 2007-05-10 |
| ZA200804896B (en) | 2009-07-29 |
| RU2008122964A (ru) | 2009-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schaller et al. | A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea | |
| Valentín et al. | Safety and efficacy of doxycycline in the treatment of rosacea | |
| Del Rosso et al. | Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea | |
| Vijayakumar et al. | Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review | |
| Park et al. | Use of oral isotretinoin in the management of rosacea | |
| US9421187B2 (en) | Phytocannabinoids for use in the treatment of intestinal inflammatory diseases | |
| WO2021014453A1 (en) | Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions | |
| Schaller et al. | State of the art: systemic rosacea management | |
| JP2018507243A5 (https=) | ||
| JP2010538066A5 (https=) | ||
| McKeage et al. | Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads) Anti-Inflammatory Dose in Rosacea | |
| BRPI0617693A2 (pt) | azitromicina para o tratamento de rosácea granulomatosa | |
| RU2014137128A (ru) | Способ лечения заболеваний кишечника с присутствием по меньшей мере одного воспалительного компонента | |
| Parodi et al. | Treatment of rosacea | |
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| CN103596565B (zh) | 塞克硝唑在口腔感染治疗中的应用 | |
| ES2929523T3 (es) | Métodos de prevención de la progresión a diabetes mellitus tipo 2 | |
| AU2015274908A1 (en) | Fixed dose combination for pain relief without edema | |
| US20220304986A1 (en) | Compositions and methods for treating acquired brain injury and post-traumatic stress disorder | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| US20070254025A1 (en) | Oral contraceptive and acne medication combination and treatment of acne with reduced side effects | |
| Leggit et al. | Secnidazole (Solosec) for Bacterial Vaginosis | |
| JP2025503136A (ja) | 前糖尿病の治療又は２型糖尿病の発症リスクを低減する際に使用するためのダパグリフロジン | |
| Awasthi et al. | Study of Oral Isotretinoin (13-Cis-Retinoic Acid) Therapy in Patients of Acne Vulgaris | |
| Slovacek et al. | Tamoxifen and arrhythmia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |